ObsEva SA
| ISIN | 🆔 |
|---|---|
| Industry | Pharmaceutical |
| Founded 📆 | 2012 |
| Founder 👔 | |
| Headquarters 🏙️ | Geneva, Switzerland |
Area served 🗺️ | Worldwide |
Key people |
|
| Products 📟 |
|
| Members | |
Number of employees | 47 (2019) |
| 🌐 Website | obseva |
| 📇 Address | |
| 📞 telephone | |
ObsEva SA is a Swiss biopharmaceutical company specializing in the development and commercialization of novel therapeutics for women’s reproductive health and pregnancy.[1]
History[edit]
Co-founded in 2012 by Dr. Ernest Loumaye, the company’s name is a portmanteau of its specialization, ‘Obstetrics’, and the location of its headquarters, ‘Geneva’.
In January 2017, the company raised $97M[2] by completing an Initial Public Offering on the NASDAQ (symbol: OBSV) and established a U.S.-based office in Boston, Massachusetts.
In July 2018, ObsEva was listed on the SIX Exchange in Zurich, Switzerland (symbol: OBSN).[3]
As of 2019, the company had 47 employees, and this is expected to grow to support the build-out of a commercial organization.
Product pipeline[edit]
ObsEva has an established late-stage clinical pipeline and development program that focuses on in vitro fertilization (IVF), endometriosis, uterine fibroids, and preterm labor.[4] The company currently holds licenses for the development and commercialization of three products:
- Nolasiban is an oral oxytocin receptor antagonist, a first-in-class compound for the improvement of IVF outcomes, which is in late stage clinical trials.
- Linzagolix (OBE-2109/KLH-2109) is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist in development for the treatment of endometriosis-associated pelvic pain, as well as heavy menstrual bleeding due to uterine fibroids, and is in late-stage clinical trials for both indications.
- OBE022 is a selective, oral prostaglandin F2α receptor antagonist used for the treatment of acute preterm labor (PTL), and is in Phase 2 clinical development.
ObsEva licensed Nolasiban and OBE022 from Merck Serono at the inception of the company and holds worldwide rights.[5] Linzagolix was licensed from Kissei Pharmaceuticals in 2015 with worldwide rights excluding some Asian countries such as Japan.[6]
References[edit]
- ↑ Constable, Simon. "ObsEva: A Small Biotech With a Promising Pipeline". www.barrons.com. Retrieved 2019-06-08.
- ↑ "OBSEVA SA (OBSV) IPO". NASDAQ.com. Retrieved 2019-06-08.
- ↑ GmbH, finanzen net. "ObsEva SA Shares to Begin Trading on SIX Swiss Exchange | Markets Insider". markets.businessinsider.com. Retrieved 2019-06-08.
- ↑ "OBSN:SIX Swiss Ex Stock Quote - ObsEva SA". Bloomberg.com. Retrieved 2019-06-08.
- ↑ "ObsEva gets funding and makes deal with Merck Serono". www.thepharmaletter.com. Retrieved 2019-06-08.
- ↑ Moore, Charles (2015-12-02). "ObsEva and Kissei Pharmaceutical Collaborate To Develop and Commercialize Endometriosis Drug KLH-2109". Endometriosis News. Retrieved 2019-06-08.
External links[edit]
This article "ObsEva SA" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:ObsEva SA. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
